All Posts

Clinical development programs optimized for regulatory approval alone systematically fail payers, physicians, and patients. This article introduces a practical framework for designing clinical trials as integrated, stakeholder-first evidence architectures.

Drug development often succeeds function by function, then fails at the system level. Approval is only one evidentiary world. Payers, physicians, patients, and guideline committees each need different proof. If programs are designed only for endpoints, access and adoption become launch problems that should have been solved much earlier.

Summary: This article examines why mechanistic success in drug development so often fails to produce patient benefit. Drawing on a century of biological thinking — from Claude Bernard’s internal milieu to Ludwik Fleck’s thought collectives — it argues that reductionism, while essential, becomes dangerous when applied to complex adaptive systems. Three case studies (the CAST antiarrhythmic trial, beta-carotene supplementation in smokers, and sepsis cytokine targeting) illustra

Sometimes, the most expensive mistakes hide in plain sight - or, more accurately, out of sight, behind a freezer door. Ask a study team why biospecimens fail, and you’ll hear about a collection technique or a courier who missed a pickup. Fair. But the quiet failure mode is storage. It’s distributed, assumed, and rarely engineered with the same rigor we give randomization or endpoint analysis. Six months later, storage comes back as assay variability, re‑runs, CAPAs, and a tim

Biospecimen logistics in clinical trials are often an afterthought—until something goes wrong. From customs delays to misrouted samples, this post explores the hidden chaos of sample shipping and how to build a resilient, operations-first strategy that ensures sample integrity, even under pressure.

When biospecimen processing fails, it’s not usually the science—it’s the gap between protocol and practice. From centrifuge errors to customs delays, silent pre-analytical variables sabotage the biospecimen lifecycle long before the assay begins. If we don’t build operational readiness into our protocols, even the most promising biomarker study can unravel before the data is even analyzed.

Biospecimen collection may seem routine, but in clinical trials, even small missteps—like a misunderstood morning urine sample—can compromise data integrity. This article explores how overlooked details in biospecimen collection can derail clinical trials and offers strategic solutions to protect your data from the first draw to final analysis.

A loose saddle, a smug horse, and an unexpected lesson in clinical trial design. This article explores how poor biospecimen planning can derail even the best biomarker strategies — and why it must be treated as a core component of trial quality, not a CRO afterthought. From patient safety to regulatory compliance, discover the 10 domains every study must get right to stay on track and upright.

Discover how operationalizing biomarker strategies can transform clinical trial outcomes. From biospecimen logistics to assay readiness, this article explores the critical role of biospecimen professionals in precision medicine. Learn how proactive planning reduces screen failures, accelerates timelines, and improves trial success rates. If you're designing biomarker-driven trials, this is your blueprint for efficient, scalable, and regulation-ready execution.

Outdated lab manuals are sabotaging clinical trials. It’s time to ditch the PDF tomes and go digital—real-time, role-based, and smart.

Rethink the biospecimen lifecycle: plan early, optimize storage, and maximize research impact for precision medicine and biomarker discovery

There is such a thing as a career ladder for biospecimen professionals Imagine receiving a party invitation in the mail - it's beautiful,...

Biospecimen management is a stand-alone, highly specialized role that requires the right expertise In our last post , we explored the...

Traditional biospecimen collection in clinical trials is outdated and burdensome. Explore why change is needed and how patient-centered inn

Biosample management isn't just moving samples; it's a critical, specialized function that ensures trial success.